X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
IPCA Labs Fact Sheet, IPCA Labs Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA Labs Fact Sheet   (IPLB)

Here is the latest financial fact sheet of IPCA Labs. For more details, see the IPCA Labs quarterly results and IPCA Labs share price and chart. For a sector overview, read our pharmaceuticals sector report.

IPCA LABS Price History

Price Rs 482.1
Mkt Cap Rs m 60,834
Vol '000 6.1
P/E X 32.3
P/CF X 16.2
EPS (TTM) Rs 14.9
% ch % -2.1
No. of shares m 126.20
% ch week % 0.7
% ch 1-mth % 1.2
% ch 12-mth % -2.0
52 week H/L Rs 656.0/437.0
(As on Jul 27, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

IPCA LABS Financials

No. of Mths
Year Ending
12
Mar-13
*
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
5-Yr Chart
Click to enlarge
IPCA LABS EQUITY SHARE DATA
High Rs567907899888643 
Low Rs320541591629503 
Sales per share (Unadj.) Rs222.9260.0249.2230.3254.4 
Earnings per share (Unadj.) Rs25.637.920.17.616.1 
Diluted earnings per shareRs25.637.920.17.616.1 
Cash flow per share (Unadj.) Rs32.546.134.420.629.8 
Dividends per share (Unadj.) Rs4.005.001.0001.00 
Adj. dividends per shareRs4.005.001.000.001.00 
Dividend yield (eoy) %0.90.70.100.2 
Book value per share (Unadj.) Rs123.1155.3174.1179.0194.6 
Adj. book value per shareRs123.1155.3174.1179.0194.6 
Shares outstanding (eoy) m126.20126.20126.20126.20126.20 
Bonus/Rights/Conversions  ESOS---- 
Price / Sales ratio x2.02.83.03.32.3 
Avg P/E ratio x17.319.137.099.535.7 
P/CF ratio (eoy) x13.615.721.736.919.2 
Price / Book Value ratio x3.64.74.34.22.9 
Dividend payout %15.613.25.006.2 
Avg Mkt Cap Rs m55,97091,35694,05795,72372,300 
No. of employees `00010.911.713.013.113.3 
Total wages/salary Rs m3,9184,9805,6516,2566,960 
Avg. sales/employee Rs Th2,578.72,798.52,416.42,213.32,413.5 
Avg. wages/employee Rs Th359.1424.7434.3476.4523.2 
Avg. net profit/employee Rs Th296.6408.1195.473.3152.4 
IPCA LABS INCOME DATA
Net Sales Rs m28,13132,81831,44429,06532,106 
Other income Rs m143223327222226 
Total revenues Rs m28,27433,04031,77129,28732,332 
Gross profit Rs m5,6017,3835,3632,8964,448 
Depreciation Rs m8671,0311,7961,6331,730 
Interest Rs m334269284319241 
Profit before tax Rs m4,5436,3063,6111,1662,703 
Minority Interest Rs m00000 
Prior Period Items Rs m-83-4900 
Extraordinary Inc (Exp) Rs m00000 
Tax Rs m1,2991,5241,019204675 
Profit after tax Rs m3,2364,7852,5429622,028 
Gross profit margin %19.922.517.110.013.9 
Effective tax rate %28.624.228.217.525.0 
Net profit margin %11.514.68.13.36.3 
IPCA LABS BALANCE SHEET DATA
Current assets Rs m13,97216,01419,34816,21917,340 
Current liabilities Rs m6,3377,91512,5179,7009,559 
Net working cap to sales %27.124.721.722.424.2 
Current ratio x2.22.01.51.71.8 
Inventory Days Days9694107105100 
Debtors Days Days5450735657 
Net fixed assets Rs m12,09814,84120,54021,42920,779 
Share capital Rs m252252252252252 
"Free" reserves Rs m15,05119,09821,56422,57824,499 
Net worth Rs m15,53819,59721,96522,59224,553 
Long term debt Rs m3,6622,9404,9874,8433,517 
Total assets Rs m26,97032,10641,24838,91739,595 
Interest coverage x14.624.513.74.712.2 
Debt to equity ratio x0.20.20.20.20.1 
Sales to assets ratio x1.01.00.80.70.8 
Return on assets %13.215.76.93.35.7 
Return on equity %20.824.411.64.38.3 
Return on capital %25.429.214.35.410.5 
Exports to sales %59.260.452.949.248.6 
Imports to sales %15.016.116.715.314.2 
Exports (fob) Rs m16,66719,83616,62414,29915,617 
Imports (cif) Rs m4,2215,2825,2474,4454,571 
Fx inflow Rs m16,76620,04816,74914,29915,617 
Fx outflow Rs m5,8047,2726,9565,8225,828 
Net fx Rs m10,96212,7769,7938,4779,790 
IPCA LABS CASH FLOW
From Operations Rs m 3,888 5,223 4,682 7,087 2,764 
From Investments Rs m -2,599 -3,690 -6,893 -2,183 -1,432 
From Financial Activity Rs m -829 -1,361 2,505 -4,615 -1,591 
Net Cashflow Rs m 460 172 294 288 -259 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 45.9%
Foreign collaborators 0.0%
Indian inst/Mut Fund 11.4%
FIIs 25.3%
ADR/GDR 0.0%
Free float 17.4%
Shareholders 36,892
Pledged promoter(s) holding 2.1%
 

Company Information

REGD OFF 48, Kandivli Industrial Estate, Kandivli (West), Mumbai - 400 067
E-MAIL investors@ipca.com WEB www.ipca.com
TELEPHONE (022) 6647 4444 FAX (022) 2868 6613
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Link Intime India, C13, Pannalal Silk Mills Cmpd., LBS Marg, Mumbai-78
AUDITOR Natvarlal Vepari & Co.
CHM: Premchand Godha (MD) COMP SEC: Harish P. Kamath (VP - Legal) YEAR OF INC: 1949 BSE CODE: 524494 FV (Rs): 2 DIV YIELD (%): 0.2

More Pharmaceuticals Company Fact Sheets:   AUROBINDO PHARMA  ALEMBIC PHARMA  SUVEN LIFE  DIVIS LABORATORIES  ALKEM LABORATORIES  

Compare IPCA LABS With:   AUROBINDO PHARMA  ALEMBIC PHARMA  SUVEN LIFE  DIVIS LABORATORIES  ALKEM LABORATORIES  

Compare IPCA LABS With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Flat in Final Hour Sell Off; HDFC Twins Surge(Closing)

Indian share markets witnessed selling pressure in the final hour of trade but still closed at a record high for a third straight session.

Views on news

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

May 18, 2017

Base price erosion in the US and lower Zetia sales impacts profits.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

More Views on News

Most Popular

Ride the Bull Wave with These Perfect Proxies to India's Growth Story(The 5 Minute Wrapup)

Jul 15, 2017

The secret of spotting multibaggers before they become a hit.

The Real Returns from Real Estate Have Been Very Low(Vivek Kaul's Diary)

Jul 17, 2017

Real estate prices across India have barely gone anywhere over the last four years. Prices have fallen in many cities over the last one-year, new data from the National Housing Bank suggests.

Trade the Markets like Roger Federer Plays Tennis(Daily Profit Hunter)

Jul 19, 2017

Trading is one of the most competitive fields in the world today. To win, you must adopt the mindset of a Grand Slam champion.

Sold Your Immoveable Property? Here Are The Tax Implications...(Outside View)

Jul 19, 2017

When you're selling an immoveable property, it becomes imperative to recognise the intricate tax implications.

Why Keeping Unrealistic Expectations From Investments Is Stupid!(Outside View)

Jul 18, 2017

When investing, keeping realistic returns is necessary and it is not the only thing you should look at.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON IPCA LABS

IPCA LABS - TEVA PHARMA COMPARISON

COMPARE IPCA LABS WITH

MARKET STATS